Home » Stocks » Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc. (XERS)

Stock Price: $5.26 USD -0.05 (-0.85%)
Updated Oct 27, 2020 12:43 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 243.21M
Revenue (ttm) 5.97M
Net Income (ttm) -119.20M
Shares Out 46.28M
EPS (ttm) -3.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $5.26
Previous Close $5.30
Change ($) -0.05
Change (%) -0.85%
Day's Open 5.30
Day's Range 5.20 - 5.38
Day's Volume 267,625
52-Week Range 1.42 - 9.69

More Stats

Market Cap 243.21M
Enterprise Value 208.69M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.28M
Float 44.67M
EPS (basic) -3.97
EPS (diluted) -3.82
FCF / Share -2.99
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 17.53M
Short Ratio 4.98
Short % of Float 39.23%
Beta 2.21
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 40.75
PB Ratio 10.44
Revenue 5.97M
Operating Income -113.34M
Net Income -119.20M
Free Cash Flow -113.64M
Net Cash 34.52M
Net Cash / Share 0.75
Gross Margin 18.67%
Operating Margin -1,898.84%
Profit Margin -1,997.00%
FCF Margin -1,903.90%
ROA -47.27%
ROE -240.39%
ROIC -89.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$11.00*
(109.32% upside)
Low
7.00
Current: $5.26
High
14.00
Target: 11.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue2.722.421.561.08
Revenue Growth12.34%55.72%44.74%-
Gross Profit1.122.421.551.07
Operating Income-122-59.34-26.63-13.23
Net Income-126-60.08-26.55-13.21
Shares Outstanding26.1112.052.031.84
Earnings Per Share-4.81-4.99-13.09-7.17
Operating Cash Flow-104-56.28-24.66-16.09
Capital Expenditures-1.11-1.51-0.70-0.04
Free Cash Flow-105-57.79-25.36-16.12
Cash & Equivalents75.5511342.0532.27
Total Debt58.3131.89--
Net Cash / Debt17.2480.7442.0532.27
Assets10912045.0033.53
Liabilities94.5544.624.952.57
Book Value14.4475.41-57.83-31.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xeris Pharmaceuticals, Inc.
Country United States
Employees 188
CEO Paul R. Edick

Stock Information

Ticker Symbol XERS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XERS
IPO Date June 21, 2018

Description

Xeris Pharmaceuticals, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.